Targeting the ELANE Pathway to Build
Next-Generation Cytotoxic Therapeutics that Stimulate the Immune System by Selectively Killing Cancer Cells
The ELANE Pathway: Unlocking a New Approach to Selective Cancer Killing
At the core of this approach is the ELANE pathway, a unique cancer-selective killing mechanism that targets an essential vulnerability shared by all cancer cells: elevated histone H1 levels. By targeting the ELANE pathway and inducing immunogenic cancer cell death, N17350 (NEU-001) and NEU-002 are designed to rapidly eliminate tumors while mobilizing an adaptive immune response, offering the potential for sustained anti-tumor immunity
Targeting the ELANE pathway enables the selective eradication of cancer cells regardless of their genetic makeup, anatomical origin, or immune status. Onchilles has rigorously validated this approach across 11 distinct cancer types, over 50 genetically diverse cell lines, and more than 20 animal models. This body of evidence supports the rapid clinical advancement of ELANE pathway-targeting therapies as a fundamentally new class of cancer-selective cytotoxic treatments.
About Onchilles Pharma
Onchilles Pharma is a global drug discovery and development company pioneering first-in-class cytotoxic therapies designed to selectively kill cancer cells while preserving and activating immune function. By harnessing the ELANE pathway, these next-generation therapeutics are designed to deliver potent and selective tumor cell destruction, overcoming the limitations of traditional chemotherapy and immunotherapy.
The company’s lead program, N17350 (NEU-001), a tumor-directed cytotoxic agent, and its intravenous counterpart, NEU-002, are advancing toward clinical trials. First-in-human studies are anticipated to begin in late 2025, focusing on head & neck, skin, lung, and triple-negative breast cancers. With an extensive translational dataset validating its approach, Onchilles is leading the way in developing safer, more effective cytotoxic therapies that not only specifically kill tumors, while sparing healthy tissue, but also activate the immune system for long-term anti-cancer immunity.
Onchilles Pharma is eliminating the trade-off between tumor-killing efficacy and immune preservation with a novel class of cytotoxic therapeutics that selectively destroy cancer cells, spare and activate the immune system
A New Class of Selective Cytotoxic Therapeutics with Unique Immune System Activation
Onchilles Pharma has established a leadership position in targeting the ELANE pathway, translating this approach into a proprietary set of molecules: N17350 (NEU-001) for intratumoral delivery and NEU-002 for intravenous delivery. Both molecules have the potential to transform cancer treatment by delivering broad tumor-killing capabilities while preserving and activating immune function—an unmet need not addressed by current cytotoxic agents or immunotherapies.
latest news
Keep up to date with all the latest news from Onchilles Pharma
